Dimetilarginina asimétrica (ADMA) en diferentes enfermedades

Asymmetrical dimethyl-arginine (ADMA) is a competitive inhibitor of endogenous eNOS, discovered in patients with renal insufficiency. Its name comes from the methyl groups bound to the guanidine nitrogen. ADMA is increased in kidney failure and other pathological situations such as hypercholesterolemia, atherosclerosis and hypertension. The increase in the concentrations of ADMA shows a significant inhibitory effect on the eNOS enzyme. Inhibition can be reduced by increasing the concentration of substrate available. Indeed, some intervention studies indicate that arginine supplements improve endothelial function in patients with coronary heart disease.